Promises and challenges of personalized medicine to guide ARDS therapy

Crit Care. 2021 Nov 23;25(1):404. doi: 10.1186/s13054-021-03822-z.


Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.

Keywords: Acute lung injury; Acute respiratory distress syndrome; COVID-19; Clinical trials; Personalized medicine.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications
  • Clinical Trials as Topic
  • Humans
  • Precision Medicine*
  • Respiratory Distress Syndrome / therapy*
  • Respiratory Distress Syndrome / virology